Chengdu Olymvax Biopharmaceuticals Inc. (688319.SS)
CNY 11.25
(2.18%)
CNY 11.25
(2.18%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 181.71 Million CNY | 365.52% |
| 2022 | 39.03 Million CNY | 1099.66% |
| 2021 | 3.25 Million CNY | 30.84% |
| 2020 | 2.48 Million CNY | -48.83% |
| 2019 | 4.85 Million CNY | 0.0% |
| 2018 | - CNY | 0.0% |
| 2017 | - CNY | 0.0% |
| 2016 | - CNY | 0.0% |
| 2015 | - CNY | -100.0% |
| 2014 | 42 Million CNY | 0.0% |
| 2013 | 42 Million CNY | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 256.24 Million CNY | 7.24% |
| 2024 Q3 | 273.94 Million CNY | 6.91% |
| 2024 Q1 | 242.43 Million CNY | 34.78% |
| 2023 Q1 | 78.04 Million CNY | 99.93% |
| 2023 Q3 | 134.78 Million CNY | 56.27% |
| 2023 Q2 | 86.25 Million CNY | 10.52% |
| 2023 Q4 | 181.71 Million CNY | 34.82% |
| 2023 FY | 181.71 Million CNY | 365.52% |
| 2022 Q3 | 49.92 Million CNY | 177.77% |
| 2022 Q1 | 8.6 Million CNY | 164.4% |
| 2022 FY | 39.03 Million CNY | 1099.66% |
| 2022 Q4 | 39.03 Million CNY | -21.82% |
| 2022 Q2 | 17.97 Million CNY | 108.93% |
| 2021 Q3 | 4.06 Million CNY | -28.75% |
| 2021 FY | 3.25 Million CNY | 30.84% |
| 2021 Q4 | 3.25 Million CNY | -19.86% |
| 2021 Q2 | 5.69 Million CNY | -12.15% |
| 2021 Q1 | 6.48 Million CNY | 160.84% |
| 2020 Q4 | 2.48 Million CNY | 0.0% |
| 2020 FY | 2.48 Million CNY | -48.83% |
| 2020 Q1 | - CNY | 0.0% |
| 2020 Q2 | - CNY | 0.0% |
| 2020 Q3 | - CNY | 0.0% |
| 2019 FY | 4.85 Million CNY | 0.0% |
| 2019 Q4 | - CNY | 0.0% |
| 2018 FY | - CNY | 0.0% |
| 2018 Q2 | - CNY | 0.0% |
| 2018 Q1 | - CNY | 0.0% |
| 2017 Q1 | - CNY | 0.0% |
| 2017 FY | - CNY | 0.0% |
| 2017 Q4 | - CNY | 0.0% |
| 2017 Q3 | - CNY | 0.0% |
| 2017 Q2 | - CNY | 0.0% |
| 2016 Q4 | - CNY | 0.0% |
| 2016 Q3 | - CNY | 0.0% |
| 2016 Q1 | - CNY | 0.0% |
| 2016 FY | - CNY | 0.0% |
| 2015 Q3 | - CNY | 0.0% |
| 2015 FY | - CNY | -100.0% |
| 2015 Q1 | - CNY | 0.0% |
| 2015 Q4 | - CNY | 0.0% |
| 2014 FY | 42 Million CNY | 0.0% |
| 2013 FY | 42 Million CNY | 0.0% |